11:03 AM EDT, 09/11/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.)

BriaCell Therapeutics ( BCTX ) shares surged over 123% in recent Wednesday trading after it reported positive overall survival data in a phase 2 late-stage metastatic breast cancer study evaluating Bria-IMT in combination with an immune check point inhibitor.

The 54-patient study showed median survival of 15.6 months in patients treated with Bria-IMT compared with 6.7 to 9.3 months for patients in other studies.

The biotechnology company said the median overall survival of 15.6 months "represents a substantial improvement" relative to prior overall survival data reported in December 2023.

Price: 1.39, Change: +0.77, Percent Change: +123.42